YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with aging The partnership is part of G…
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases…
GSK has pulled off a 52.5% share price gain over the past 5 years, yet with recent weakness on the screen, the live question for investors is whether that track record lines up with what the company is actually earning today. The issue is…
CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and unsuppressed HIV Results build on LATIT…
Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady…
Fresh funding from the Gates Foundation for AN2 Therapeutics' tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group's boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the…
Hatteras Venture Partners – Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Par…
GSK GSK and Sanofi SNY are two major European drugmakers with diversified portfolios spanning vaccines, specialty medicines and other pharmaceutical products. GSK has a strong presence in specialty medicines, vaccines and general medicines…
Merck MRK and partner Daiichi Sankyo announced that they have voluntarily withdrawn a regulatory filing with the FDA seeking accelerated approval for an investigational antibody-drug conjugate (ADC) called ifinatamab deruxtecan in lung can…
GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren't giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm's pr…
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Ch…
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHME…
The Rockefeller Foundation becomes the first national philanthropy to commit to this regional initiative, triggering a matching commitment from the John M. Belk Endowment. $3.2 million in previously raised funds awarded to 11 community col…
ALK Abello Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product StrategyTina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective 1 October 2026. ALK…
At the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare and PAC recognize a decade of U=U and its landmark impact on the HIV community The organizations also announce, "Undetectable Voices," a new initiative elevating community vo…
GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately support…
GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell…
GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. Under the agreement, GSK will pay Chimagen an upfront payment in ex…
GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more…
Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare announced it has funded 230 community-based organizations this year to strengthen essential HIV services and help connect people to HIV prevention and care DURHAM, N.C.…
GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Shares of Incyte INCY have rallied 23% year to date compared with the industry's growth of 5.2%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame. Much of this rally came after the company rep…
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro (zidesamtinib), for the first-line treatment of patients with advanced or metastatic ROS1-positive non-small cell l…
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China. Continue Reading
GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than…
GSK plc's GSK Specialty Medicines business has become the company's most important growth engine. The segment includes HIV, Respiratory, Immunology & Inflammation (RI&I) and Oncology, and its performance has been substantially stronger tha…
GHO Capital Vivid brings over 30 years of operational and financial leadership in healthcare and life sciences, being a founder of LivaNova PLC, led OPEN Health as Interim Group CEO, and held senior roles at GlaxoSmithKline, Allergan, and…
Company Logo Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Ti…
Company Logo One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 319 Targets/Antigens/Armor and 1,200+ Funding Rounds as GlaxoSmithKline, BioNTech, and Inovio Lead a Field That Saw 76 New Vaccines in 2024/25 Alone Dublin, S…
GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer. Bepirovirsen, which is now branded as Hibsago, was approved by Japan, marking the drug's first authorization…
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market. Continue Reading
Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a significant milestone for the company, which gets an opportunity to establish a foothold in another multibillion-dollar m…
HUTCHMED (China) Limited — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chin…
GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II study, which showed that the company's…
GSK stock has delivered a strong 54.4% total return over the past five years, yet current valuation checks still suggest the shares lean cheap rather than fully priced in. That mix of solid long term gains and a high value score raises the…
GSK (LSE:GSK) has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The Japanese approval follows Phase III trial data that showed significant f…